Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 1
1990 2
1991 3
1992 12
1993 10
1994 12
1995 21
1996 17
1997 23
1998 25
1999 33
2000 34
2001 30
2002 56
2003 53
2004 62
2005 65
2006 92
2007 110
2008 94
2009 107
2010 114
2011 150
2012 159
2013 226
2014 259
2015 309
2016 305
2017 337
2018 283
2019 354
2020 353
2021 31
Text availability
Article attribute
Article type
Publication date

Search Results

3,364 results
Results by year
Filters applied: . Clear all
Page 1
Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Rutgeerts P, et al. N Engl J Med. 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516. N Engl J Med. 2005. PMID: 16339095 Free article. Clinical Trial.
BACKGROUND: Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. METHODS: Two randomized, double-blind, placebo-controlled stu …
BACKGROUND: Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an estab …
Ulcerative colitis.
Danese S, Fiocchi C. Danese S, et al. N Engl J Med. 2011 Nov 3;365(18):1713-25. doi: 10.1056/NEJMra1102942. N Engl J Med. 2011. PMID: 22047562 Review. No abstract available.
Ulcerative colitis: epidemiology, diagnosis, and management.
Feuerstein JD, Cheifetz AS. Feuerstein JD, et al. Mayo Clin Proc. 2014 Nov;89(11):1553-63. doi: 10.1016/j.mayocp.2014.07.002. Epub 2014 Sep 8. Mayo Clin Proc. 2014. PMID: 25199861 Review.
Ulcerative colitis is a chronic idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation that starts in the rectum and extends proximally. ...In some cases, extraintestinal manifestations may be present as well. In the right clinical se
Ulcerative colitis is a chronic idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation that st
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
Singh S, Fumery M, Sandborn WJ, Murad MH. Singh S, et al. Aliment Pharmacol Ther. 2018 Jan;47(2):162-175. doi: 10.1111/apt.14422. Epub 2017 Dec 4. Aliment Pharmacol Ther. 2018. PMID: 29205406 Review.
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC). AIM: To assess comparative efficacy and safety of different therapies as first-line (biologic-naive) and second-line (prior exposure to anti-t
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC). AIM: …
Acute severe ulcerative colitis: from pathophysiology to clinical management.
Hindryckx P, Jairath V, D'Haens G. Hindryckx P, et al. Nat Rev Gastroenterol Hepatol. 2016 Nov;13(11):654-664. doi: 10.1038/nrgastro.2016.116. Epub 2016 Sep 1. Nat Rev Gastroenterol Hepatol. 2016. PMID: 27580687 Review.
Ulcerative colitis is a common chronic inflammatory disease of the colon and rectum, resulting from a dysregulated immune response towards intraluminal antigens in a genetically predisposed host. The disease has a varying extent and severity. Approximately 20% of pa
Ulcerative colitis is a common chronic inflammatory disease of the colon and rectum, resulting from a dysregulated immune resp
Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.
Jeong DY, Kim S, Son MJ, Son CY, Kim JY, Kronbichler A, Lee KH, Shin JI. Jeong DY, et al. Autoimmun Rev. 2019 May;18(5):439-454. doi: 10.1016/j.autrev.2019.03.002. Epub 2019 Mar 4. Autoimmun Rev. 2019. PMID: 30844556 Review.
Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). ...The use of immunomodulatory agents in the induction or maintenance phase of UC and CD using immunomodulators appeared to be more effective than placebo,
Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). ...The use of im
Special considerations for biologic medications in pediatric ulcerative colitis.
Jerger L, Hyams JS. Jerger L, et al. Expert Opin Biol Ther. 2020 Apr;20(4):429-435. doi: 10.1080/14712598.2020.1685492. Epub 2019 Oct 29. Expert Opin Biol Ther. 2020. PMID: 31652087 Review.
Introduction: More extensive disease, high rates of corticosteroid refractory and dependent disease, and the potential impact of disease on growth and development differentiate inflammatory bowel disease in children from adults. This is particularly evident in ulcerative
Introduction: More extensive disease, high rates of corticosteroid refractory and dependent disease, and the potential impact of disease on …
Anti TNF-alpha therapy for ulcerative colitis: current status and prospects for the future.
Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Pugliese D, et al. Expert Rev Clin Immunol. 2017 Mar;13(3):223-233. doi: 10.1080/1744666X.2017.1243468. Epub 2016 Oct 14. Expert Rev Clin Immunol. 2017. PMID: 27687496 Review.
Anti TNF-alpha agents have become a significant advance in the management of ulcerative colitis, proving to induce, with rapid onset, clinical and endoscopic remission. However, there is still a considerable unmet medical need in ulcerative colitis
Anti TNF-alpha agents have become a significant advance in the management of ulcerative colitis, proving to induce, wit …
VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice.
Wang CS, Li WB, Wang HY, Ma YM, Zhao XH, Yang H, Qian JM, Li JN. Wang CS, et al. World J Gastroenterol. 2018 Oct 7;24(37):4254-4262. doi: 10.3748/wjg.v24.i37.4254. World J Gastroenterol. 2018. PMID: 30310258 Free PMC article.
METHODS: C57BL/6 mice were administered AOM/DSS to develop the ulcerative colitis (UC) carcinogenesis model. Mice were treated with 5-ASA (75 mg/kg/d), VSL#3 (1.5 10(9) CFU/d), or 5-ASA combined with VSL#3 by gavage from the day of AOM injection for three months (fi …
METHODS: C57BL/6 mice were administered AOM/DSS to develop the ulcerative colitis (UC) carcinogenesis model. Mice were treated …
Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.
Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Reinglas J, et al. World J Gastroenterol. 2018 Aug 28;24(32):3567-3582. doi: 10.3748/wjg.v24.i32.3567. World J Gastroenterol. 2018. PMID: 30166855 Free PMC article. Review.
The past decade has brought substantial advances in the management of inflammatory bowel diseases (IBD). The introduction of tumor necrosis factor (TNF) antagonists, evidence for the value of combination therapy, the recognition of targeting lymphocyte traffi …
The past decade has brought substantial advances in the management of inflammatory bowel diseases (IBD). The introduction of tumor
3,364 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page